Description

Merck Just Matched Gilead — But The REAL Story Is Portfolio Defense!

When Merck & Co. reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched the efficacy of Gilead Sciences’ Biktarvy, it wasn’t just another clinical headline. It was a strategic signal. The study showed non-inferiority at 48 weeks in treatment-naïve adults with HIV-1, with a similar safety profile. In plain English, Merck proved a two-drug pill can stand shoulder to shoulder with the world’s best-selling three-drug HIV therapy. That matters on its own. But it matters even more because Keytruda, Merck’s cancer powerhouse, faces U.S. patent expiry starting in 2028. Management has been vocal about building “green shoots” beyond oncology. This HIV data is one of the clearest examples yet. Investors aren’t just looking for science wins. They’re looking for durable revenue engines that can soften the Keytruda patent cliff. This one checks more than a few boxes.